PHARMACEUTICAL COMPOSITION COMPRISING HISTONE H3K9 METHYLTRANSFERASE G9A FOR PREVENTING AND TREATING MYELOPROLIFERATIVE DISORDERS

摘要

The present invention provides a pharmaceutical composition for preventing or treating myeloproliferative disorders, comprising one or more materials selected from the group consisting of histone H3K9 methyltransferase G9a protein, a segment thereof, an activator thereof, an expression regulator thereof and a histone H3K9 methyltransferase G9a-encoding gene, and a pharmaceutically acceptable carrier. The histone H3K9 methyltransferase G9a according to the present invention inhibits the transcription of JAK2, and promotes ATRA-induced cell differentiation of the promyelocytic leukemia cell line HL-60 in a differentiation inducing therapy using all-trans retinoic acid (ATRA, tretinoin) as a vitamin inducer, instead of a bone fracture treatment, and thus is useful in the form of a cell therapeutic agent or a protein therapeutic agent for the treatment or prevention of diseases associated with JAK2 activation and mutation, specifically, myeloproliferative disorders.